[go: up one dir, main page]

CR20110154A - ANTI-EGFR / ANTI-IGF-1R BIESPECTIFIC ANTIBODIES - Google Patents

ANTI-EGFR / ANTI-IGF-1R BIESPECTIFIC ANTIBODIES

Info

Publication number
CR20110154A
CR20110154A CR20110154A CR20110154A CR20110154A CR 20110154 A CR20110154 A CR 20110154A CR 20110154 A CR20110154 A CR 20110154A CR 20110154 A CR20110154 A CR 20110154A CR 20110154 A CR20110154 A CR 20110154A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
egfr
biespectific
production
Prior art date
Application number
CR20110154A
Other languages
Spanish (es)
Inventor
Ulrich Brinkmann
Rebecca Croasdale
Wilma Lau
Christian Gerdes
Eike Hoffmann
Christian Klein
Klaus-Peter Kuenkele
Wolfgang Schaefer
Jan Olaf Stracke
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CR20110154A publication Critical patent/CR20110154A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención esta relacionada con anticuerpos biespecíficos frente a EGFR y frente a IGF-1R, métodos para su producción, composiciones farmacéuticas que contienen dichos anticuerpos y usos de los mismos.The present invention is related to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

CR20110154A 2008-09-26 2011-03-22 ANTI-EGFR / ANTI-IGF-1R BIESPECTIFIC ANTIBODIES CR20110154A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08016952 2008-09-26

Publications (1)

Publication Number Publication Date
CR20110154A true CR20110154A (en) 2011-05-12

Family

ID=40352483

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110154A CR20110154A (en) 2008-09-26 2011-03-22 ANTI-EGFR / ANTI-IGF-1R BIESPECTIFIC ANTIBODIES

Country Status (1)

Country Link
CR (1) CR20110154A (en)

Similar Documents

Publication Publication Date Title
CO6362023A2 (en) ANTI-EGFR / ANTI-IGF-1R BIESPECIFIC ANTIBODIES
ECSP11011387A (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
AR076194A1 (en) BISPECIFIC ANTIBODIES ANTI-ERBB-2 / ANTI-C-MET
CO6551674A2 (en) ANTI-HER3 ANTIBODIES AND USES OF THE SAME
CO7081144A2 (en) Bispecific antibodies against human tweak and human il17 and their uses
ECSP12011701A (en) HUMANIZED ANTI-CDCP1 ANTIBODIES
PE20160506A1 (en) SPECIFIC BISPECIFIC ANTIBODIES FOR FAP AND DR5, SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
CR20120215A (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME
MX338078B (en) ANTI-SCLEROSTINE ANTIBODY CRYSTALS AND FORMULATIONS OF THE SAME.
CR20160206A (en) Compositions and methods for antibodies that target C5 complement protein
CO6351794A2 (en) ANTI-VEGF / ANTI-ANG-2 BIESPECIFIC ANTIBODIES
CR20120184A (en) MONOCLONAL ANTIBODIES AGAINST PROGASTRINE AND ITS USES
CO2018003452A2 (en) Bispecific antibodies against human cd20 and human transferrin receptor and methods of use
BR112015006824A2 (en) bispecific igg antibody, method for producing a bispecific igg antibody, antibody, pharmaceutical composition and use of a bispecific igg antibody
UY31611A1 (en) COMPOUNDS THAT INCLUDE A CICLOBUTOXI GROUP
CR11623A (en) COMPOUNDS
ECSP14000329A (en) MOLECULES THAT ARE ANTIBODIES WITH SPECIFICITY FOR HUMAN OX40
ECSP14004976A (en) ANTI-IL-36R ANTIBODIES
UY33310A (en) ESTEREOSELECTIVE SYNTHESIS OF ASSETS CONTAINING PHOSPHORUS
NI201400061A (en) ANTI - PHF - TAU ANTIBODIES AND THEIR USES
GT201300306A (en) ANTI-ANGPTL3 ANTIBODIES AND USES OF THE SAME
ECSP088778A (en) FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY
MX385858B (en) ANTIBODIES THAT BIND TO NOTUM PECTINACETYLESTERASE.
UY31871A (en) COMPOUNDS THAT INCLUDE A CICLOBUTOXI GROUP
ECSP11011190A (en) ANTI-RHD MONOCLONAL ANTIBODIES